108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE
U.S. FDA Approves Ziihera® with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Zymeworks to Acquire, Investor Presentation
Announces Share Repurchase Program of up to $125 Million of its Common Stock
Provides Corporate Update and Reports First Quarter 2026 Financial Results
Appoints Kristin Stafford as Chief Financial Officer
Enter into $250 Million Royalty-Backed Note Financing
Earnings Release
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
RW
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report